Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients

Core Insights - Novo Nordisk has reduced the cash price of its diabetes treatment Ozempic to less than half of its monthly list price in response to political pressure for lower drug prices in the U.S. [1] Pricing and Accessibility - Patients can now pay $499 in cash per month for Ozempic, available in three dose sizes, through various platforms including the drug's official website and Novo Nordisk's patient assistance program [2] - GoodRx will also offer Ozempic and its weight loss counterpart Wegovy at the same price of $499 per month, accessible at over 70,000 pharmacies nationwide, enhancing affordability for patients [3] - This cash-pay offering aims to increase access for eligible Type 2 diabetes patients who lack insurance coverage for the weekly injection [3]